治疗帕金森病的肉毒毒素:一个系统性审查
Ethan Slouha1, Fadi Ibrahim1, Sarah Esposito1
1Pharmacology, St. George's University School of Medicine, St. George's, GRD.
Cureus
|March 4, 2024
概括
毒素 (BoNT) 注射显著改善了帕金森病 (PD) 患者的震, dystonia,疼痛,,以及过度活动的膀症状,提高了他们的生活质量. 然而,BoNT在PD中没有显示出步态结的显著改善.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 运动障碍 运动障碍
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,影响生活质量 (QoL).
- 虽然存在常规治疗方法,但正在探索新的治疗途径,例如毒素 (BoNT) 用于症状管理.
- 众所周知,神经毒素BoNT抑制了乙胆分泌,为特定的PD相关症状提供了潜在的益处.
研究的目的:
- 评估毒素 (BoNT) 注射在管理与帕金森病 (PD) 相关的各种症状中的疗效.
- 评估BoNT对PD患者的生活质量 (QoL) 的影响.
- 审查关于治疗PD症状的BoNT治疗结果的现有文献.
主要方法:
- 对PubMed,ScienceDirect和ProQuest的文章进行系统审查,使用关键词"肉毒素和帕金森病".
- 遵守系统审查和元分析 (PRISMA) 准则的首选报告项目.
- 包含和排除标准适用于23,803篇初始文章,最终选择了41项研究.
主要成果:
- 毒素A型 (BoNT-A) 显著改善了PD中常见的运动障碍,以及主观和客观的QoL测量.
- BoNT注射有效地减少了疼痛, (过度的唾液流出) 和过度活跃的膀症状,从而改善了QOL.
- 无论是BoNT-A还是BoNT-B,都没有显著改善另一种常见的PD相关运动障碍 - - 步态结 (FOG).
结论:
- 毒素 (BoNT) 通过减轻关键症状,为帕金森病患者改善生活质量提供了显著的好处.
- 博恩特是有效的运动症状,如震和 dystonia,以及非运动症状,包括尿和尿道问题.
- 需要进一步的研究来探索BoNT对其他PD症状 (如和便秘) 的潜力.
相关概念视频
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Parkinson's Disease: Overview
544
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
544
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
680
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
680
Skeletal Muscle Relaxants: Therapeutic Uses
482
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
482
Myasthenia Gravis: Overview and Treatment
1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
420
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
420


